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Dopamine Gene Profiling to Predict Impulse Control and
Effects of Dopamine Agonist Ropinirole
Hayley J. MacDonald1, Cathy M. Stinear1, April Ren1, James P. Coxon2, Justin Kao3,
Lorraine Macdonald3, Barry Snow3, Steven C. Cramer4, and Winston D. Byblow1
Abstract
■ Dopamine agonists can impair inhibitory control and cause
impulse control disorders for those with Parkinson disease
(PD), although mechanistically this is not well understood. In
this study, we hypothesized that the extent of such drug effects
on impulse control is related to specific dopamine gene poly-
morphisms. This double-blind, placebo-controlled study aimed
to examine the effect of single doses of 0.5 and 1.0 mg of the
dopamine agonist ropinirole on impulse control in healthy
adults of typical age for PD onset. Impulse control was mea-
sured by stop signal RT on a response inhibition task and by
an index of impulsive decision-making on the Balloon Analogue
Risk Task. A dopamine genetic risk score quantified basal
dopamine neurotransmission from the influence of five genes:
catechol-O-methyltransferase, dopamine transporter, and those
encoding receptors D1, D2, and D3. With placebo, impulse con-
trol was better for the high versus low genetic risk score groups.
Ropinirole modulated impulse control in a manner dependent
on genetic risk score. For the lower score group, both doses
improved response inhibition (decreased stop signal RT)
whereas the lower dose reduced impulsiveness in decision-
making. Conversely, the higher score group showed a trend
for worsened response inhibition on the lower dose whereas
both doses increased impulsiveness in decision-making. The
implications of the present findings are that genotyping can
be used to predict impulse control and whether it will improve
or worsen with the administration of dopamine agonists. ■
INTRODUCTION
Impulse control is required to evaluate the potential con-
sequences of a decision, modify behavior, and suppress
undesirable actions. Dopamine is necessary for impulse
control, whereas dysfunctional levels of frontostriatal
dopamine are associated with worse control (Pattij &
Vanderschuren, 2008). People with Parkinson disease
(PD) are commonly prescribed dopaminergic medica-
tion, and 14–20% (Weintraub, Papay, & Siderowf, 2013;
Weintraub et al., 2010) develop some form of impulse
control disorder (ICD) as a result. It has been suggested
that difficulty in performing executive tasks requiring
high levels of impulse control may signal an increased
risk for the development of ICDs (Poletti & Bonuccelli,
2012). However, the mechanisms of susceptibility to
ICD development are not well understood.
One working hypothesis is that ICDs result from a hy-
perdopaminergic state of the mesocorticolimbic system
in early PD, which is then exacerbated by dopaminergic
medication. Dopaminergic medications augment depleted
nigrostriatal dopamine, but a lack of network specificity
consequently increases dopamine within the relatively
preserved medial pFC and ventral striatum (Vaillancourt,
Schonfeld, Kwak, Bohnen, & Seidler, 2013; Sawamoto
et al., 2008; Cools, 2006). Subsequent dopamine dysreg-
ulation within the mesocorticolimbic system may cause
deviation from optimal function, adversely influencing
motor and cognitive control.
Variation in dopamine-regulating genes can influence
impulse control (Nandam et al., 2013; Nemoda, Szekely, &
Sasvari-Szekely, 2011) and may affect response to dopami-
nergic medication. Of particular interest are polymorphisms
within genes that affect dopamine neurotransmission such
as catechol-O-methyltransferase (COMT); dopamine trans-
porter (DAT); and DRD1, DRD2, and DRD3, which regu-
late the D1, D2, and D3 receptors. D1 and D2 are the
most widely expressed dopamine receptors throughout
the brain (Nemoda et al., 2011); are central components
of motor, cognitive, and limbic cortico-basal ganglia net-
works (Goto & Grace, 2005; Surmeier, Song, & Yan,
1996; Gerfen et al., 1990); and are specifically implicated
in impulse control (Ghahremani et al., 2012; Eagle et al.,
2011; Colzato, van den Wildenberg, Van der Does, &
Hommel, 2010; Hamidovic, Dlugos, Skol, Palmer, & de
Wit, 2009; Comings et al., 1997). D3 receptors are abun-
dant in the mesocorticolimbic system (Gurevich & Joyce,
1999), and the variation within DRD3 has been associated
with increased risk of ICDs in PD patients on dopaminergic
medication (Lee et al., 2009). The DAT enzyme is predom-
inantly responsible for synaptic dopamine degradation
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within the striatum, whereas COMT is important for do-
pamine degradation in pFC (Robbins & Arnsten, 2009;
Diamond, Briand, Fossella, & Gehlbach, 2004), and both
influence impulse control (Congdon, Constable, Lesch, &
Canli, 2009; Congdon, Lesch, & Canli, 2008). The combina-
tion of polymorphisms across these five genes has bearing
on a person’s overall level of dopamine neurotransmission.
The additive effect of these polymorphisms can be repre-
sented as a dopamine gene score and has been shown to
predict effects of levodopa on cortical plasticity and motor
learning in healthy participants (Pearson-Fuhrhop, Minton,
Acevedo, Shahbaba, & Cramer, 2013).
Ropinirole has been associated with ICDs (Weintraub,
2009). It is a non-ergoline D2-like dopamine receptor
agonist, showing little or no interaction with nondopami-
nergic receptors. Like other dopamine agonists, ropini-
role mimics the dopamine neurotransmitter and directly
activates receptors in the absence of dopamine (Tintner
& Jankovic, 2003; Brooks, 2000). The preferential affinity
for ropinirole is to activate D3 > D2 > D4 receptors
(Coldwell, Boyfield, Brown, Hagan, & Middlemiss, 1999;
Perachon, Schwartz, & Sokoloff, 1999) with D3 and D2
being the primary targets. Ropinirole is widely distributed
throughout the body and rapidly absorbed after oral
administration.
To investigate why ICDs are developed by some peo-
ple, but not others, we examined how the dopamine
agonist ropinirole interacts with dopamine gene poly-
morphisms to influence impulse control. This study was
conducted with healthy adults spanning the typical age of
onset for PD. Participants were administered ropinirole
or placebo and, 1 hr later, performed computerized tasks
to measure impulse control. We hypothesized that im-
pulse control would be modulated by ropinirole and that
this would occur in a manner affected by dose and the
participant’s genetically determined dopamine profile.
Specifically, we predicted that ropinirole would improve
impulse control in participants with lower basal dopa-
mine neurotransmission, that is, lower dopamine genetic
risk scores (GRSs). Conversely, we predicted that ropini-
role would worsen impulse control in participants with
higher basal dopamine neurotransmission (higher
GRS). Global cognitive function was not expected to be
affected by ropinirole and served as a control measure.
METHODS
Participants
Healthy adults of typical age for PD onset were screened
to determine eligibility for the study. Inclusion criteria
were age 40–75 years old, no neurological or cognitive
impairment, nonsmoker, normal or corrected-to-normal
vision, and no contraindications to ropinirole or domper-
idone. Potential participants were screened by a neurol-
ogy registrar (JK) for contraindications. A research nurse
(LM) took a single blood sample for genetic analysis. The
study was approved by the University of Auckland human
participant ethics committee and health and disability
Ethics Committee, and written informed consent was ob-
tained from each participant.
Pharmacological Intervention
Participants were orally administered a single dose of pla-
cebo, 0.5 or 1.0 mg of the dopamine agonist ropinirole
(Janssen-Cilag, Beerse, Belgium) in three experimental
sessions with a double-blind, randomized, counter-
balanced design. A dose of 1.0 mg was chosen as it is
around the commonly prescribed daily therapeutic start-
ing dose for PD (Matheson & Spencer, 2000), and this
dose has been tolerated in studies with healthy partici-
pants (Monte-Silva et al., 2009; Acton & Broom, 1989).
A dose of 0.5 mg was included to investigate the dose
dependency of ropinirole effects. Overall, these two doses
are low compared with replacement doses for PD. The
experimental sessions were spaced at least 1 week apart
to prevent cumulative drug effects. To minimize drug-
induced systemic side effects of ropinirole, 20 mg of
domperidone (Janssen-Cilag, Beerse, Belgium) was admin-
istered orally, and participants refrained from caffeine
and alcohol on the days of testing.
Experimental Protocol
Before the first experimental session, all participants
completed the Beck Depression Inventory-II (Beck,
Steer, & Brown, 1996) and Barratt Impulsiveness Scale-
II (Patton, Stanford, & Barratt, 1995) tests and were as-
sessed by the research nurse on the motor section of
the Unified Parkinson’s Disease Rating Scale.
Each experimental session began with administration
of domperidone and ropinirole/placebo (after at least
an hour of fasting) 1 hr before beginning the computer-
ized impulse control tasks. This timing interval coincides
with peak ropinirole blood concentrations (Brefel et al.,
1998).
The order of tasks was always anticipatory response in-
hibition (ARI), Balloon Analogue Risk Task (BART), and
Central Nervous Systems Vital Signs (CNSVS) test battery.
Collection and analysis of tasks and questionnaires were
performed blind to medication (placebo, dose) and
genotype.
ARI Task
The ARI task was controlled using custom software writ-
ten with MATLAB (The MathWorks, Natick, MA), inter-
faced with two custom-made switches, an A/D USB
interface (National Instruments, Austin, TX) and micro-
controller (Eleven Freetronics, Victoria, Australia). The
goal of the task was to lift the index fingers in time to
stop rising indicators at a fixed target on a computer dis-
play (Figure 1A). Participants were seated 1 m in front of
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a computer display. Their forearms rested on a table, po-
sitioned midway between supination and pronation. The
medial aspect of each index finger was used to depress
the switches (index finger adduction). Each trial com-
menced after a variable delay. Both indicators “filled” up-
ward at equal rates, reaching the target line in 800 msec
and terminating their rise in 1000 msec, unless stopped
prior by releasing either or both switches.
The default response on go trials (GG) required the
release of both switches in time to stop the indicators
at the target. Only go trials were presented in the first
two blocks and as 66% of trials in the remaining eight
blocks. Upon trial completion, visual feedback indicated
“success” (bars stopped within 30 msec of target) or
“miss” to emphasize that trials were to be performed as
accurately as possible. The remaining one third of trials
were stop trials, where one or both indicators stopped
automatically before reaching the target, cueing the par-
ticipant to inhibit responding with the corresponding
digit(s). There were three types of stop trials: stop both
(SS), when both indicators stopped automatically, and
partial stop trials stop left–go right (SG) and go left–stop
right (GS). For each stop trial type, the indicator was ini-
tially set to stop at 500 msec. A staircase procedure ad-
justed the indicator stop time dynamically throughout
the task in 25-msec increments to convergence on a
50% success rate.
EMG data were recorded from bilateral first dorsal in-
terosseous (FDI) muscles. Electrodes were placed in a
belly tendon montage, and ground electrodes were
placed over the posterior surface of the hand. EMG sig-
nals were amplified (CED 1902, Cambridge, UK), band-
pass filtered (20–1000 Hz), and sampled at 2 kHz (CED
1401, Cambridge, UK). Data were saved for later offline
analysis using Signal (CED, Cambridge, UK) and custom
software (MATLAB R2012b).
Balloon Analogue Risk Task
The BART was controlled using Inquisit 3 (version
3.0.6.0, Millisecond Software, Seattle, WA). To perform
the BART, participants used a mouse to click on an icon
that read “Pump up the balloon” to incrementally inflate a
red balloon on a laptop screen (Figure 1B). Each press
would either (i) incrementally inflate the balloon, causing
a visual (and auditory) increase in balloon size, adding
5 cents to the monetary reward, or (ii) burst the balloon
(with realistic visual and auditory effect), resulting in no
money earned for that balloon. At any time the participant
could click a “Collect $$$” icon to end the trial and the
current amount would add to their total along with rein-
forcing auditory feedback. Each balloon was set to explode
in a randomly determined manner anywhere from the first
pump to filling the entire screen. Participants were told
that they would be given a monetary reward equivalent
to the final money counter. The balloon (i.e., trial) num-
ber, accumulated money for the current balloon, number
of pumps for the current balloon, and total winnings thus
far were displayed to participants.
Participants completed a single block of 30 trials. The
probability of explosion was determined by an array from
1 to 85. Each button press randomly selected a number
without replacement. Selection of number one was des-
ignated as a balloon explosion. Successive pumps result-
ed in increasing risk but diminishing returns.
CNSVS Test Battery
The CNSVS consisted of seven tests examining composite
memory, verbal memory, visual memory, working mem-
ory, processing speed, executive function, RT, complex
attention, cognitive flexibility, and sustained attention.
The four-part continuous performance test was added
to six of the core tests (excluding the finger tapping test).
Standardized instructions were given. Test scoring was
automated and generated from primary scores based on
correct responses, error responses, number of responses,
and RTs. Cognitive domain scores were computed as nor-
malized standard scores (mean of 100) representing raw
scores relative to age-matched normative data. An overall
neurocognitive index (NCI) score was the average of stan-
dard scores for composite memory, RT, complex atten-
tion, and cognitive flexibility.
Genotyping
DNA was extracted from whole blood samples by salt pre-
cipitation. Genotyping for DRD1 rs4532, DRD2 rs1800497,
DRD3 rs6280 and COMT rs4680 single-nucleotide polymor-
phisms (SNPs) was performed using the Agena MassArray
iPLEX assay (Agena Bioscience, San Diego, CA). The assay
consisted of an initial locus-specific polymerase chain reac-
tion, followedby single base extension usingmass-modified
dideoxynucleotide terminators of an oligonucleotide
Figure 1. (A) Visual display for the ARI task showing successful Go
(GG, left), Stop Both (SS, middle), and Partial trial (Go Left–Stop Right,
GS, right). (B) Visual display at the start of BART.
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primer (Gabriel, Ziaugra, & Tabbaa, 2009). The four SNPs
were included in one multiplex well after accounting for
the presence of proximal SNPs. Analysis was performed
on the Bruker Mass Spectrometer (Billerica, MA) using pa-
rameters optimized for iPLEX chemistry, allowing allele-
specific single base extensions to be resolved. The 40 base
pair variable number of tandem repeats in the untranslated
regulatory region of the DAT gene (rs28363170) under-
went polymerase chain reaction with a labeled primer
(Mata, Hau, Papassotiropoulos, & Hertwig, 2012) and was
assayed separately on a 3130XL genetic analyzer. The
results were analyzed using GeneScan (Luxembourg) and
PeakScanner (Waltham, MA) software.
A participant’s GRS represented the additive effects of
the five polymorphisms affecting dopaminergic neuro-
transmission, as has been described and validated previ-
ously in relation to motor learning, Levodopa effects, and
cortical plasticity (Pearson-Fuhrhop et al., 2013), and more
recently depression (Pearson-Fuhrhop et al., 2014). Each
gene was initially equally scored based on the absence
(0) or presence (1) of polymorphic alleles that increase
dopamine neurotransmission (Table 1). Dopamine GRS
could range from 0 (lowest basal dopamine neurotrans-
mission) to 5 (highest neurotransmission). If an effect
of GRS was present, subsequent analyses investigated
a weighted GRS generated by substituting each single
gene score into the model. We also investigated remov-
ing each gene sequentially in order of lowest weighting,
to determine their contributions to the composite score
(Pearson-Fuhrhop et al., 2013).
Dependent Measures
ARI Task
Lift times (LTs) were determined for successful go (GG)
and partial (GS, SG) trials. Average LTs were calculated
after removing outliers (±3 SD; 1.0 ± 0.1% and 0.2 ±
0.2%, respectively). All LTs are reported in milliseconds
relative to the target.
For stop trials, stop signal RT (SSRT), indicator stop
time (staircased to 50% success), and percentage of
successful trials were determined. SSRT was calculated
using the integration method (Verbruggen, Chambers,
& Logan, 2013; Logan & Cowan, 1984). SSRT on stop
both (SS) trials was the primary dependent measure for
this task, as it signifies the efficacy and latency of the in-
hibitory process in pure response inhibition (RI). Indica-
tor stop time, instead of SSRT, was used as a more direct
measure of performance on Partial trials because the cal-
culation of SSRT was not possible in instances where par-
ticipants couldn’t successfully perform these trials.
Balloon Analogue Risk Task
The number of button presses made on trials where a re-
ward was collected (“win”) were used to compute the pri-
mary measure of interest. The number of button presses
on trials when the balloon burst (“loss”) were necessarily
constrained by software and not used in the analysis. The
average number of button presses was calculated for win
trials after a loss and for win trials after a win. For the
effect of positive reinforcement, the difference between
these two averages was normalized to the mean number
of presses after loss trials (the “losses” cancel). The effect
of negative reinforcement was normalized to the mean
number of presses after win trials (the “wins” cancel).
Proportions farther from zero indicate greater behavior
modification as a result of reinforcement on a trial-by-trial
basis and are indicative of more impulsive decision-making
because behavior is too readily modified.
CNSVS Test Battery
The primary dependent measure was NCI. Higher values
represent better global cognitive function. Working
memory was calculated separately from correct–incorrect
responses on the four-part continuous performance test.
Statistical Analysis
LTs were subjected to a repeated-measures ANOVA
with a 3 Dose (PLA, ROP 0.5, ROP 1.0) × 2 Digit (Left,
Right) × 2 Trial type (Go, Partial) design. All remaining
dependent measures were analyzed with a mixed-effects
linear regression model in SPSS Statistics (version 21,
IBM Corporation, North Castle, NY). Each dependent
measure was modeled as a function of Dose (PLA, ROP
0.5, ROP 1.0), GRS, Dose × GRS interaction, and Age.
Measures from the CNSVS were standardized scores so
Age was removed from the model when predicting these
Table 1. Occurrence of Polymorphisms and Values for GRS
DRD1 rs4532 DRD2 rs800497 DRD3 rs6280 DAT rs28363170 COMT rs4680
A/A A/G G/G Glu/Glu Glu/Lys Lys/Lys Ser/Ser Ser/Gly Gly/Gly 9/9 9/10 10/10 Val/ Val Val/Met Met/Met
Score 0 1 1 1 0 0 0 1 1 1 1 0 0 1 1
Predict freq 0.29 0.50 0.14 0.68 0.29 0.03 0.33 0.49 0.18 0.09 0.42 0.49 0.28 0.50 0.23
Actual freq 0.21 0.64 0.14 0.68 0.29 0.04 0.36 0.43 0.21 0.04 0.54 0.43 0.25 0.54 0.21
DAT 11 alleles scored as 10 alleles. DRD1 = dopamine receptor D1; DRD2 = dopamine receptor D2; DRD3 = dopamine receptor D3; Lys = lysine;
Glu = glutamic acid; Ser = serine; Gly = glycine; Val = valine; Met = methionine.
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dependent variables. A subject-specific random effect fac-
tor (μ) accounted for between-subject variation and all
other effects (β0 – β4) were fixed.
y ¼ β0 þ β1 Doseð Þ þ β2 GRSð Þ þ β3 Dose GRSð Þ
þ β4 Ageð Þ þ μ
To explore single-gene relationships, each single-gene
score in Table 1 was independently inserted into the
model in place of GRS. Model degrees of freedom were
calculated using the Satterthwaite method.
Chi-square tests were used to assess Hardy–Weinberg
equilibrium for each gene. Missing data were replaced by
average of row and column means. The criterion for sta-
tistical significance was α = 0.05. All results are reported
as group means ± SE.
RESULTS
Thirty-seven participants were screened, 33 recruited,
and 30 completed all experimental sessions. Two with-
drew due to drug-induced side effects (nausea: 1, dizzi-
ness: 1) and one due to scheduling problems. Generally,
the medications were tolerated with the following excep-
tions for ropinirole (nausea: 2, vomiting: 1, drowsiness:
5) and domperidone (dry mouth: 1, headache: 1). Two
participants were unable to adhere to one or more pro-
tocols. Results are reported for the remaining 28 partici-
pants. Demographic details and clinical assessment
scores are presented in Table 2; F statistics, p values,
and ηp
2 effect sizes are reported for the mixed-effects
linear regression models in Tables 3 and 4. All genes were
in Hardy–Weinberg equilibrium (.12 < p < .89, Table 1).
The distribution of dopamine GRS is shown in Figure 2A.
Scores of 2 and 3 were grouped (Low, n = 12; age = 44–
73 years) as were scores of 4 and 5 (High, n = 16; age =
44–75 years). No participant had the rare GRS of 0 or 1.
ARI Task
Go Trials
Go trials were completed successfully with LTs occurring
32 ± 2 msec after the target as is typical for older adults
with this task (Coxon, Van Impe, Wenderoth, & Swinnen,
2012). There was a main effect of Trial type (F(1, 26) =
127.9, p < .001) with LTs delayed to an average of 96 ±
6 msec after the target on Partial trials. There was a main
effect of Digit (F(1, 26) = 6.4, p = .018) with right LT
faster than left LT when collapsed across Trial type and
Dose (57 ± 5 msec vs 70 ± 3 msec). There was no effect
of Dose (F(1, 26) = 0.6, p = .557) or any interactions (all
ps > .218).
Stop Both Trials
Stop both trials were performed as expected with a
success rate just above 50% (58.6 ± 1.8%). The model
predicted that SSRT for SS trials was dependent on Dose
( p = .025), the Dose × GRS interaction ( p = .029,
Table 3), and the intercept (β0 = 243 msec, t(27) = 7.2,
p < .001). Predicted SSRT decreased by 66 msec with
0.5 mg ROP (t(27) = −2.6, p= .013) and by 61 msec with
1.0 mg ROP (t(27) =−2.4, p= .021). The pattern of inter-
action results for predicted SSRT is evident in the sample
data (Figure 2B). Post hoc tests revealed that participants
with a low GRS had longer SSRTs at baseline (236 ±
10 msec) than those with high scores (199 ± 7 msec,
unpaired t test: t(26) = 3.0, p = .008). SSRT decreased
with ROP for lowGRS (paired t tests: 0.5 mg, 211± 9msec,
t(11) = −2.8, p = .008; 1.0 mg, 214 ± 9 msec, t(11) =
−2.2, p = .025) but tended to increase with ROP for high
scores, especially at the lower dose (paired t tests: 0.5 mg,
213 ± 6 msec, t(15) = 1.5, p= .072; 1.0 mg, 205 ± 8 msec,
t(15) = 0.6, p = .280).
Entered into the model separately, no single gene sig-
nificantly interacted with ROP to predict SSRT (Dose ×
Gene interactions: .06 < p < .64). DRD3 had the highest
weighting (0.32), then DAT (0.25), DRD1 (0.22), COMT
(0.14), DRD2 (0.08). The Weighted GRS produced very
similar results with a fixed effect of Dose ( p = .010)
and Dose ×Weighted GRS interaction ( p= .012). Remov-
ing the lowest-weighted gene DRD2 from the Weighted
GRS had a negligible effect on the Dose × Weighted
GRS interaction ( p = .011). Removing COMT weakened
the interaction ( p = .029) and removing DRD1 produced
no Dose × Weighted GRS interaction ( p = .159). At least
four genes were necessary to explain the Dose × GRS
interaction for ARI task (SSRT) performance.
Partial Stop Trials
On average, partial stop trials were more difficult than
stop both trials, with success rates just below 50% (SG,
41.8 ± 3.3%; GS, 36.4 ± 3.8%). Eleven participants were
unable to complete any successful trials for at least one
Table 2. Participant Demographics and Clinical
Assessment Scores
Age (years) 60 (44–75)
Weight (kg) 73 (52–96)
Sex 15F/13M
Ethnicity 27 White, 1 Maori
BIS-II 59 (38–77)
UPDRS (III) 4 (0–14)
BDI-II 3 (0–15)
MoCA 28 (26–30)
Values are mean (range) unless otherwise noted. BIS = Barratt Impul-
siveness Scale (max 120); UPDRS (III) = Unified Parkinson’s Disease
Rating Scale motor scores (max 56); BDI = Beck Depression Inventory
(max 63); MoCA = Montreal Cognitive Assessment (max 30).
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Partial trial type in at least one session, even with the
staircase procedure. Two participants were unable to per-
form any SG trials successfully (n = 26) and one could
not perform GS trials successfully (n = 27).
The indicator stop time on GS and SG trials was depen-
dent on the intercept (t(26) = 4.3, p < .001 and t(25) =
5.9, p < .001, respectively) but was not dependent on
Dose, GRS, or a Dose × GRS interaction (all ps > .179).
Partial GS trials only showed a fixed effect of Age ( p <
.001). With each year increase in age, there was a 9-msec
increase in the predicted indicator stop time relative to
target.
Balloon Analogue Risk Task
Using the unweighted GRS to predict effect of negative
reinforcement, there was a fixed effect of Dose ( p =
.024) with the predicted number of presses after loss tri-
als decreasing less with 0.5 mg ROP (t(27) = −2.3, p =
.027) than PLA, with no difference between 1.0 mg ROP
and PLA (t(27) = 0.3, p = .786, Table 3). There was a
Dose×GRS interaction ( p= .031; Figure 2D). Participants
with a low GRS made fewer impulsive decisions on 0.5 mg
ROP (PLA: 0.10 ± 0.05; ROP: 0.02 ± 0.05) whereas those
with a high GRSmademore (PLA: 0.05± 0.05; ROP: 0.12±
0.05), although these differences did not reach significance
in post hoc testing ( p > .17). A similar pattern of means
were observed for positive reinforcement (Figure 2C),
but with no fixed effect of Dose ( p = .091) or Dose ×
GRS interaction ( p = .107, Table 3).
Entered into the model separately, the DAT polymor-
phism interacted with ROP to predict an effect of both
Table 3. Main Effects from Mixed-effects Linear Regression Models
Dependent Measure Model Term
Unweighted Weighted
F df p ηp
2 F df p ηp
2
SSRT Dose 4.0 2.51 .025 0.14 5.0 2.51 .010 0.16
GRS 1.6 1.30 .211 0.05 1.3 1.30 .271 0.04
Age 1.8 1.30 .187 0.05 1.5 1.30 .230 0.05
Dose × GRS 3.8 2.51 .029 0.13 4.8 2.51 .012 0.16
Positive reinforcement Dose 2.5 2.54 .091 0.08 3.5 2.54 .037 0.11
GRS 0.2 1.31 .639 0.00 0.3 1.31 .585 0.01
Age 0.0 1.31 .904 0.00 0.0 1.31 .882 0.00
Dose × GRS 2.3 2.54 .107 0.08 4.4 2.54 .017 0.14
Negative reinforcement Dose 4.0 2.54 .024 0.13 5.4 2.53 .008 0.17
GRS 0.2 1.32 .668 0.01 0.2 1.31 .699 0.01
Age 0.0 1.32 .862 0.00 0.0 1.31 .895 0.00
Dose × GRS 3.7 2.54 .031 0.12 6.4 2.53 .003 0.19
NCI Dose 0.5 2.48 .636 0.02
GRS 5.9 1.27 .022 0.18
Dose × GRS 0.3 2.48 .711 0.01
Working memory Dose 2.7 2.48 .080 0.10
GRS 3.7 1.26 .066 0.12
Dose × GRS 2.5 2.48 .089 0.09
Bold indicates p > 05.
Table 4. Main Effects in Balloon Analogue Risk Task Using
DAT Score
Dependent Measure Model Term F df p ηp
2
Positive reinforcement Dose 3.0 2.55 .059 0.10
DAT 1.7 1.32 .205 0.05
Age 0.0 1.32 .915 0.00
Dose × DAT 5.6 2.55 .006 0.17
Negative reinforcement Dose 4.2 2.54 .021 0.13
DAT 1.1 1.31 .313 0.03
Age 0.0 1.31 .862 0.00
Dose × DAT 6.9 2.54 .002 0.20
Bold indicates p > 05.
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negative (Dose × DAT Score interaction: p = .002;
Figure 2F) and positive reinforcement (Dose × DAT
Score interaction: p = .006; Figure 2E; Table 4). No other
gene could predict this interaction (Dose × Gene inter-
actions: .27 < p < .96). At baseline, participants with a
DAT score of 0 (DAT0, lower dopamine neurotransmis-
sion, n = 12) made more impulsive decisions than DAT1
participants (higher dopamine transmission, n = 16)
Figure 2. (A) Distribution of GRSs. SSRTs (B) and impulsive decision-making (C–F) for low versus high neurotransmission. PLA = placebo; ROP =
ropinirole. †p = .072. *p < .05. **p < .01.
MacDonald et al. 915
after negative (DAT0: 0.19 ± 0.04; DAT1: 0.02 ± 0.04, un-
paired t test: t(26) = 3.6, p = .001) and positive reinforce-
ment (DAT0: 0.28 ± 0.08; DAT1: 0.00 ± 0.04, unpaired t
test: t(26) = 3.0, p = .008). DAT0 participants reduced im-
pulsivity with 0.5 mg ROP (paired t tests: both reinforce-
ment t(11) > −1.9, p < .044) but not 1.0 mg ROP
(paired t tests: both p > .176). Conversely, DAT1 partici-
pants increased impulsivity with 0.5 mg (paired t tests:
both reinforcement t(15) > 2.6, p < .009) and 1.0 mg
ROP (paired t tests: both t(15) > 3.7, p < .002).
DAT had the highest weighting (0.60) in the Weighted
GRS, then DRD2 (0.24), DRD3 (0.08), COMT (0.05),
DRD1 (0.03). The Weighted GRS produced a fixed effect
of Dose ( p = .037) and Dose × Weighted GRS interac-
tion ( p = .017) for positive reinforcement and the effect
of Dose ( p = .008) and Dose × Weighted GRS interac-
tion ( p = .003) for negative reinforcement (Table 3). Re-
moving the lowest weighted genes in order (DRD1,
COMT, DRD3) had a negligible effect on the Dose ×
Weighted GRS interaction for negative (all ps < .004)
and positive reinforcement (all ps > .015). Therefore, the
DAT polymorphism alone accounted for the Dose × GRS
interaction for BART performance.
CNSVS Test Battery
The predicted NCI score was not dependent on Dose or
a Dose × GRS interaction (Table 3). There was a signifi-
cant intercept (β0 = 112, t(27) = 18.6, p < .001) and a
fixed effect of GRS ( p = .022). However, there was no
systematic increase or decrease in NCI as a function of
GRS (t(27) = −1.5, p = .130), and post hoc tests indi-
cated no difference in NCI between GRS. Predicted work-
ing memory was not dependent on Dose, GRS, or a
Dose × GRS interaction (all ps > .065; Table 3), only
the intercept (β0 = 115, t(27) = 9.1, p < .001).
DISCUSSION
This study produced several novel findings. Impulse con-
trol of healthy adults differed between those with high
and low levels of basal dopamine neurotransmission, as
determined by a dopamine GRS. A single administration
of ropinirole interacted with genetic variations in dopa-
mine transmission to affect impulse control in predict-
able ways. In support of our hypothesis, RI improved
for those with a lower GRS when given a single dose of
ropinirole and tended to worsen for those with higher
scores. Whereas a polygenic risk score was necessary to
account for SSRT during RI, the DAT polymorphism
alone determined impulsive decision-making during the
BART. Ropinirole decreased impulsive decision-making
for those with the lower DAT score and increased it for
those with the higher DAT score. Ropinirole had no ef-
fect on global cognitive function so the results appear
to be specific to impulse control.
Consistent with previous studies, we propose an
inverted-U relationship between dopamine levels and
impulse control (Farrell, Tunbridge, Braeutigam,&Harrison,
2012; Congdon et al., 2009). Figure 3 illustrates how the
GRS may determine a person’s starting position on the
curve. People with higher scores have closer to optimal
levels of dopamine for RI, whereas people with lower
scores may sit lower on the curve. In this study, this was
verified by faster SSRTs for participants with a higher
GRS. Adults with more optimal levels of dopamine neuro-
transmission also demonstrate greater neural activation
within the RI network (Congdon et al., 2009). Interestingly,
Congdon and colleagues did not find an effect on SSRT
when contrasting polymorphisms within COMT and DAT
individually. Variation in DRD2 expression alone can mod-
ulate RI (Ghahremani et al., 2012; Colzato et al., 2010;
Hamidovic et al., 2009). The current study extends these
findings by quantifying the influence of a greater range of
polymorphisms that influence dopamine neurotransmis-
sion and demonstrating that a dopamine GRS can be used
to predict baseline measures of RI.
A single administration of ropinirole temporarily
shifted participants rightward along the inverted-U curve
either toward or beyond optimal dopamine concentra-
tions for RI (Figure 3). Both doses of ropinirole shifted
participants with a lower GRS toward optimal levels, as
evident by improved SSRTs. For participants with a higher
GRS, basal dopamine may have been closer to optimal
levels. In this case, 0.5 mg ropinirole caused a nonsig-
nificant worsening of SSRT ( p = .072). Combined, these
results indicate that there was no dose-dependent effect
of ropinrole on RI, perhaps because of the low dosages
of ropinirole used in this study. The absence of dose
Figure 3. Relationship
between dopamine
neurotransmission and
RI (left) and decision-making
(right). Squares: GRSs 2, 3 for
RI, DAT0 for decision-making;
circles: GRSs 4, 5 for RI, DAT1
for decision-making. PLA =
placebo; ROP = 0.5 mg
ropinirole.
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dependency may also be due to only two participants be-
ing at the highest range of basal neurotransmission (GRS
of 5). Previously, a single administration of up to 1.0 mg
ropinirole (Monte-Silva et al., 2009) and 0.5 mg pramipex-
ole (Pizzagalli et al., 2008) was shown to influence plastic-
ity and reinforcement learning in healthy participants,
respectively. Consistent with these findings, the divergent
effect of ropinirole on RI in this study was evident during
peak dopamine agonist concentrations.
The current study extends the use of a dopamine poly-
genic score into the context of impulse control. Variation
within DRD3 has been associated with increased risk of
ICDs in PD patients on dopaminergic medication (Lee
et al., 2009), and the D3 receptor is a target of ropinirole
(Matheson & Spencer, 2000). The present results indi-
cate that DRD3 was weighted most heavily to predict
the interaction between GRS and ropinirole on SSRT.
However, variation in DRD3 alone could not account
for the effects of ropinirole. RI might better be predicted
by quantifying widespread dopaminergic neurotransmis-
sion rather than DRD3 alone, because of the differential
expression of dopamine genes across the network of
brain regions implicated in RI. This includes frontal cor-
tical regions (e.g., right inferior frontal gyrus) in which
COMT has a larger impact on dopamine neurotransmis-
sion. A four-gene score that omits DRD2 may be sufficient
to capture the effect of ropinirole on RI and warrants fur-
ther investigation. However, a strength of the five-gene
score is that it was an a priori, hypothesis-driven score
based on previously published literature (Pearson-Fuhrhop
et al., 2013, 2014). The ARI task might be clinically useful in
the context of ICDs. Baseline measures of SSRT and do-
pamine GRS indicate a person’s starting position on the
inverted-U curve and, combined, may identify those at risk
of developing ICDs when taking dopamine agonists.
Surprisingly, the DAT polymorphism alone predicted
impulsive decision-making. The DAT protein is involved
in synaptic dopamine degradation and is particularly im-
portant in the striatum. Lower DAT activity results in less
reuptake of synaptic dopamine and consequently higher
levels of dopamine neurotransmission (VanNess, Owens,
& Kilts, 2005; Heinz et al., 2000). DAT1 participants (DAT
score = 1) had higher basal levels of striatal dopamine
neurotransmission and better impulse control than
DAT0 participants. Those with DAT1 made fewer impul-
sive decisions on placebo after both positive and negative
reinforcement. This is consistent with individual differ-
ences in general risk taking on the BART, with lower
DAT activity being associated with less risky behavior
(Mata et al., 2012). Mata and colleagues inferred risk
taking from average total number of button presses on
collected trials. This study quantified behavioral modifica-
tion on a trial-by-trial basis as a result of rewards and
losses to assess impulsive decision-making (Ashenhurst,
Bujarski, Jentsch, & Ray, 2014) and extend the findings
of Mata and colleagues to show how DAT polymorphism
dictates impulsive decision-making.
The DAT protein influences basal dopamine neuro-
transmission and tonic dopamine activity within the dor-
sal and ventral striatum. Striatal dopamine is associated
with reinforcement learning from positive and negative
outcomes (Cox et al., 2015; Frank, Moustafa, Haughey,
Curran, & Hutchison, 2007). Increasing tonic dopamine
activity in the ventral striatum beyond optimal levels dis-
rupts behavior modification (Goto & Grace, 2005;
Schultz, 2002). In this study, ropinirole interacted with
the DAT polymorphism in a predictable way. This can
be likened to shifting a participant rightward along an
inverted-U curve either toward optimal levels of striatal
dopamine neurotransmission (DAT0) or beyond them
(DAT1). Figure 3 depicts the working hypothesis (green
arrow) that 1.0 mg ropinirole degrades decision-making
in people with lower striatal dopamine neurotransmis-
sion, perhaps because striatal dopamine levels were near
optimal at 0.5 mg. This may explain why 0.5 mg ropini-
role improved decision-making whereas 1.0 mg degraded
it. When combined with DAT genotyping, the BART may
assist in identifying people who may be more susceptible
to developing a hyperdopaminergic state of the ventral
striatum when given dopamine agonist medication.
Performance on the bimanual ARI task was as expected
for healthy older adults. Go LTs were typical for this age
range (Coxon et al., 2012), occurring later than for youn-
ger adults performing an identical task (MacDonald,
Stinear, & Byblow, 2012). As expected, LTs on Partial tri-
als were delayed (MacDonald, Coxon, Stinear, & Byblow,
2014; MacDonald et al., 2012; Coxon, Stinear, & Byblow,
2007, 2009). Furthermore, partial cancellation on GS tri-
als was more difficult with increasing age (Coxon et al.,
2012, 2014). In contrast to SSRT obtained from Stop Both
trials, performance on Partial trials was not influenced by
GRS or ropinirole dosage. Compared with simple RI, par-
tial movement cancellation involves more complex neu-
ral mechanisms as the noncued movement component
still needs to be executed. The delay in the executed
component may reflect processes of inhibition, repro-
gramming, and initiation (MacDonald et al., 2014; Coxon
et al., 2007, 2009). Partial trials may therefore engage
mechanisms beyond pure impulse control as opposed
to SSRT from Stop Both trials, and this may explain the
differential sensitivity to dopaminergic factors between
these two trial types.
The sample size obtained within the recruitment period
was less than anticipated and is a limitation in this study.
Our target sample size was 50 based on the study by
Pearson-Fuhrhop et al. (2013). Our smaller sample did
not capture the full range of dopamine GRSs, particularly
scores of 0 or 1. We are therefore not able to comment on
the effect of GRSs 0 and 1 in the context of impulse con-
trol and ropinirole, limiting the comparison between our
study and the ones by Pearson-Fuhrhop et al. (2013,
2014). Sample size also necessitated limiting the number
of predictors in the model. For example, weight was not
included to avoid overparameterization. However, this was
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not considered to have a major impact on our results as
shown previously for gene score predictions of motor
learning (Pearson-Fuhrhop et al., 2013). It is not currently
known whether or not the present results are specific to
ropinirole because no other dopaminergic medications
were investigated in this study.
In summary, the effect of ropinirole on impulse control
can be conceptualized as shifting people rightward along
an inverted-U curve to their benefit or detriment. The net
result from the rightward shift depends on basal levels of
dopamine neurotransmission, which are significantly influ-
enced by genetic factors. Genetic variation in dopamine
neurotransmission may have only modest behavioral con-
sequences for healthy individuals; however, there may be
more serious implications for those prescribed large doses
of dopaminergic medications over a longer time period, as
is common for the treatment of PD. This study provides
preliminary evidence that dopaminergic genotyping
combined with baseline measures of RI and impulsive
decision-making may be useful for identifying people at
risk of developing ICDs on dopamine agonists. It remains
to be determined if such an approach could lead to better
individualized treatments for PD.
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